FcRn blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo) coverage for gMG and CIDP
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0111N alerts
Get alerted when Policy 2026D0111N changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and prior authorization requirements for provider‑administered FcRn blocker therapies (rozanolixizumab, efgartigimod products) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) under Sierra Health and Life medical benefit.
Added HCPCS code J9256 and removed C9305 from the applicable codes list.
Coverage Criteria for FcRn Blocker Therapies
Rystiggo — Initial Therapy
Rystiggo (rozanolixizumab‑noli) for generalized myasthenia gravis (AChR+ or MuSK+): Covered when ALL of the following are met
For AChR‑positive patients: history of failure of >=2 immunosuppressive agents over >=12 months OR failure of >=1 immunosuppressive therapy plus >=4 courses of plasmapheresis and/or IVIG over >=12 months; for MuSK‑positive patients: history of failure of >=1 immunosuppressive agent over >=12 months
Rystiggo — Continuation Therapy
Rystiggo — Continuation of Therapy: Covered when ALL of the following are met
Improvement is defined as >=2 point reduction in MG‑ADL from pretreatment baseline
Vyvgart / Vyvgart Hytrulo — Initial Therapy (gMG)
Vyvgart and Vyvgart Hytrulo for AChR‑positive generalized myasthenia gravis: Covered when ALL of the following are met
Vyvgart / Vyvgart Hytrulo — Continuation Therapy (gMG)
Vyvgart and Vyvgart Hytrulo — Continuation of Therapy (gMG): Covered when ALL of the following are met
Improvement is defined as >=2 point reduction in MG‑ADL from pretreatment baseline
Vyvgart Hytrulo — Initial Therapy (CIDP)
Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP): Covered when ALL of the following are met
Electrodiagnostic criteria include motor distal latency prolongation in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolonged F‑wave latency in 2 nerves; absence of F‑waves in >=1 nerve; partial motor conduction block in >=1 nerve; abnormal temporal dispersion in >=2 nerves; or distal CMAP duration increase in >=1 nerve
Vyvgart Hytrulo — Continuation Therapy (CIDP)
Vyvgart Hytrulo — Continuation of Therapy (CIDP): Covered when ALL of the following are met
Covered indications and supporting clinical criteria
Covered when clinical evidence and indication align with trial populations and FDA indications
gMG AChR-positive indication
- Baseline clinical severity: Baseline MG‑ADL score consistent with trial enrollment (e.g., ≥5 used in efgartigimod IV trials; rozanolixizumab trials enrolled patients with MG‑ADL ≥3 with ≥3 non‑ocular points) and MGFA class II‑IV
Reflects trial inclusion criteria
- Stable concomitant therapy: On stable dose of MG therapies (AChE inhibitors, steroids, or non‑steroidal immunosuppressive therapies) prior to treatment
Reflects trial requirement
- Serum IgG requirement: Serum IgG at or above trial‑specified minimum (e.g., ≥6 g/L for efgartigimod IV; ≥5.5 g/L for rozanolixizumab)
Safety enrollment criterion
The policy explicitly prohibits concurrent administration of these FcRn‑targeting agents with certain other immunomodulatory therapies. Concomitant use with a complement inhibitor (e.g., eculizumab, ravulizumab, zilucoplan), another FcRn blocker (e.g., Vyvgart, Vyvgart Hytrulo when the requested product is Rystiggo or vice versa), or immune globulin (IVIG/SCIG) is not permitted and will render the combination non‑covered under this policy. This restriction applies to both initiation and continuation authorizations and mirrors the language used for Rystiggo and Vyvgart/Vyvgart Hytrulo in the criteria sets.
When documenting therapy plans, providers must confirm the patient is not receiving any of the excluded concomitant agents and that the requested FcRn blocker will be dosed per FDA labeling and at the minimum interval from the prior treatment cycle specified for the product (e.g., no sooner than 63 days for Rystiggo; no sooner than 50 days for Vyvgart/Vyvgart Hytrulo).
Information about FDA approval is provided for context only. FDA approval alone is not a basis for coverage; coverage determinations are made using the clinical criteria and prior authorization requirements specified in this policy.
If the patient does not meet the required initiation criteria (for example, lacks the required antibody positivity, does not meet the MG‑ADL minimum, or lacks diagnostic confirmation for CIDP), the request should be managed as not medically necessary. Providers should submit complete medical records documenting diagnosis, serologic testing, baseline clinical scores, prior therapy trials, or reasons why specified prior therapies were contraindicated or not tolerated to support reconsideration.
Where appropriate, consider alternative evidence‑based therapies that meet the patient’s diagnostic and prior‑therapy profile (e.g., standard immunosuppressive agents, IVIG, or plasmapheresis for gMG or CIDP), and document rationale for the selected therapeutic approach and any contraindications to the preferred options.
Medicare currently has no National Coverage Determination (NCD) or local LCD/LCA addressing Vyvgart, Vyvgart Hytrulo, or Rystiggo. In the absence of an applicable Medicare NCD/LCD, coverage for these agents depends on the payer’s specific policy and the member’s plan benefits; therefore, lack of a local Medicare coverage article could result in non‑coverage for some members if the payer’s medical policy is not met.
Note that general Medicare billing rules still apply for Part B outpatient drugs furnished incident to a physician’s service; however, preferred therapy criteria described in this policy are not applicable to Medicare Advantage members per CMS guidance.
Billing and Coding
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
| G70.00 | Myasthenia gravis without (acute) exacerbation |
| G70.01 | Myasthenia gravis with (acute) exacerbation |
| J9256 | added HCPCS code (as listed in policy) |
| C9305 | removed HCPCS code (was previously listed) |
Provider Actions, Prior Authorization, and Documentation
Prior authorization: submit full medical records showing all initiation criteria
Submit a prior authorization request with complete medical records demonstrating the patient meets the initiation criteria for the requested FcRn blocker (antibody status, MGFA class II–IV, MG‑ADL baseline score, prior therapy history) and that the patient has not previously failed the same agent.
- Include chart notes and laboratory values showing diagnosis of gMG or CIDP as applicable.
- Confirm patient has not failed a previous course of the requested agent (Rystiggo, Vyvgart, or Vyvgart Hytrulo).
- For gMG, document positive serologic testing (anti‑AChR or anti‑MuSK per agent) and MGFA class II–IV.
- Provide MG‑ADL total score at initiation (see thresholds).
Use updated HCPCS codes (J9256 added; C9305 removed)
Request authorization using the policy's updated HCPCS code list; the policy added J9256 and removed C9305 in the latest annual edit.
Prior therapy requirements: document failed immunosuppressive and IVIG/plasmapheresis trials
Document prior therapy trials as required before initiation: history of failure of at least two immunosuppressive agents over ≥12 months, or failure of ≥1 immunosuppressive plus ≥4 courses of plasmapheresis/IVIG over ≥12 months (criteria vary by agent and antibody status).
- For AChR‑positive gMG (Vyvgart/Vyvgart Hytrulo/Rystiggo AChR): either ≥2 immunosuppressive agent failures over ≥12 months OR ≥1 immunosuppressive failure plus ≥4 plasmapheresis/IVIG courses over ≥12 months.
- For MuSK‑positive Rystiggo patients: refer to the Rystiggo-specific requirement (failure of ≥1 immunosuppressive agent over ≥12 months where specified).
- For CIDP (Vyvgart Hytrulo): document trial and failure (≥2 months) or intolerance/contraindication to corticosteroids and trial and failure (≥3 months) of IVIG/SCIG or documented intolerance/contraindication per CIDP criteria.
Step edits and Medicare note: commercial step edits possible; Medicare has no NCD/LCD
Be aware payer step edits and Medicare considerations: preferred‑therapy or step edits may be applied for commercial members, while preferred therapy criteria are not applicable for Medicare Advantage members and Medicare lacks an NCD/LCD for these agents.
- Commercial plans may apply preferred‑therapy criteria or step edits consistent with policy logic.
- Medicare: no NCD or LCD exists for these agents; preferred therapy criteria is not applicable for Medicare Advantage members but Part B coverage rules apply per benefit manuals.
Required documentation to support PA: labs, scores, electrodiagnostics, and prior therapy history
Include the following documentation with PA submission: chart notes, laboratory results (including antibody testing and serum IgG), baseline and follow‑up MG‑ADL scores, MGFA class documentation, electrodiagnostic testing for CIDP, and a detailed prior therapy history with dates and outcomes.
- Positive serologic test results (anti‑AChR and/or anti‑MuSK where applicable) and serum IgG level if available.
- MG‑ADL total score at baseline and documentation of any subsequent MG‑ADL changes.
- MGFA clinical classification documented in chart notes.
- Electrodiagnostic reports meeting EFNS/PNS criteria for CIDP when applicable.
- Detailed prior therapy history: immunosuppressant names, durations, dates of IVIG/plasmapheresis courses, and reasons for discontinuation or intolerance.
Suggested supporting clinical documentation: trial‑aligned inclusion data
Provide suggested supporting clinical documentation that aligns with trial inclusion criteria: MGFA class II–IV (or II–IVa for rozanolixizumab), baseline MG‑ADL thresholds used in trials, stable concomitant MG therapy, and minimum serum IgG per trial enrollment.
- Efgartigimod (Study 1) trial criteria: MGFA class II–IV, MG‑ADL ≥5, stable MG therapy, serum IgG ≥6 g/L.
- Rozanolixizumab trial criteria: MGFA class II–IVa, MG‑ADL ≥3 with ≥3 non‑ocular points, stable MG therapy, serum IgG ≥5.5 g/L.
- For CIDP, documentation per EFNS/PNS criteria and evidence of responder status in an initial open‑label phase may support requests.
Triggers for possible denial: missing diagnosis, serology, MGFA class, MG‑ADL, or prior therapy evidence
Requests lacking required diagnostic or prior‑therapy documentation may be denied. Common denial triggers include absence of confirmed diagnosis, missing positive serologic testing for the applicable antibody, no MGFA class II–IV documentation, MG‑ADL below policy threshold, or insufficient prior immunosuppressive/IVIG/plasmapheresis history.
- Missing positive anti‑AChR or anti‑MuSK serology as required by the agent's criteria.
- No documentation of MGFA clinical class II–IV at initiation.
- MG‑ADL total score below policy minimum (e.g., <5 for most initiation criteria).
- Insufficient evidence of required prior failures of immunosuppressants or IVIG/plasmapheresis as specified.
Coverage limitations: FDA approval is informational; local and Medicare coverage may be absent
Do not assume coverage solely because a product is FDA‑approved; the policy states FDA approval is informational only and Medicare lacks an NCD/LCD — absence of local coverage or member‑specific benefits may result in non‑coverage.
- FDA approval does not guarantee coverage under this medical policy.
- Medicare: no NCD/LCD exists for these agents; local coverage absence may affect reimbursement depending on plan benefits.
Background and Mechanism
Efgartigimod (including the coformulation with hyaluronidase) and rozanolixizumab are biologic agents that target the neonatal Fc receptor (FcRn) to reduce circulating IgG, including pathogenic autoantibodies such as anti‑AChR. Efgartigimod alfa acts as an FcRn blocker and has been studied both as an IV formulation and as a subcutaneous formulation coformulated with hyaluronidase to facilitate SC administration; hyaluronidase transiently increases subcutaneous tissue permeability to allow larger‑volume SC dosing.
Rozanolixizumab is likewise an FcRn‑targeting monoclonal agent developed for subcutaneous administration in generalized myasthenia gravis. Clinical trials for these agents used disease‑specific outcome scales (e.g., MG‑ADL and QMG) and defined responder thresholds that underpin the policy’s initiation and continuation criteria.
Definitions and Responder Criteria
Revision History and Policy Changes
Updated applicable HCPCS codes: added J9256 and removed C9305; previous policy version archived.
Policy number: 2026D0111N. Effective date: 2026-01-01. Scope: Defines medical necessity criteria and prior authorization requirements for provider‑administered FcRn blocker therapies (Rystiggo, Vyvgart, Vyvgart Hytrulo) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) under the Sierra Health and Life medical benefit.
Change status: This policy is modified with an operational coding update — the applicable HCPCS code list was revised effective 01/01/2026 (an HCPCS code was added and a previously listed code removed). Initial and reauthorization maximum periods are unchanged and limited to 12 months per the criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.